Cytosorbents Corp
CTSO
60 hedge funds and large institutions have $20.7M invested in Cytosorbents Corp in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 21 closing their positions.
86% more call options, than puts
Call options by funds: $39K | Put options by funds: $21K
1.47% less ownership
Funds ownership: 35.56% → 34.09% (-1.5%)
23% less funds holding
Funds holding: 78 → 60 (-18)
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
39% less capital invested
Capital invested by funds: $33.9M → $20.7M (-$13.2M)
86% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$295K |
| 2 |
AC
Avenir Corporation
Alexandria,
Virginia
|
+$293K |
| 3 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$255K |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$248K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$764K |
| 2 |
Millennium Management
New York
|
-$514K |
| 3 |
Morgan Stanley
New York
|
-$401K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$278K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$222K |
CTSO Hedge Fund Activity: Q3 2022 in Review
60 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cytosorbents Corp (CTSO) for Q3 2022, worth a combined $20.7M — down 39% from $33.9M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CTSO and 3 opened new positions — a net loss of 18 holders — while 19 trimmed existing stakes and 13 added.
The largest buyer was Neuberger Berman Group, adding an estimated $295K. The largest seller was Royce & Associates, exiting entirely with an estimated $764K sold.
- 60 institutional investors held Cytosorbents Corp (CTSO) as of Q3 2022, down from 78 in Q2 2022.
- Funds reported $20.7M of Cytosorbents Corp stock for Q3 2022, down 39% quarter-over-quarter.
- 3 funds opened new Cytosorbents Corp positions in Q3 2022 and 21 closed out, a net change of -18 holders.
- The largest Cytosorbents Corp buyer in Q3 2022 was Neuberger Berman Group, an estimated $295K added.
- The largest Cytosorbents Corp seller in Q3 2022 was Royce & Associates, an estimated $764K sold.
Based on aggregated 13F filings for Q3 2022.